Effect of Acupuncture at HT-7 (Shenmen) and GV-20 (Baihui) on Anxiety and Cardiovascular Functions in Generalized Anxiety Disorder: A Randomized Controlled Trial.

Int J Psychiatry MedOct 16, 2025 (epub)
Clinical ResearchPsychiatryCardiology

G Dhanushya Devi, A Mooventhan, L Nivethitha et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed acupuncture at HT-7 and GV-20 for anxiety and cardiovascular measures in 60 adults aged 20–55 with generalized anxiety disorder. Participants received either acupuncture or supine breath-awareness meditation for 20 minutes daily over 10 days. Anxiety scores decreased significantly more in the acupuncture group than in the control group (P < .001). Between-group differences were not significant for systolic blood pressure (P = .686), diastolic blood pressure (P = .998), or pulse rate (P = .925).

Key findings

  • Anxiety levels fell significantly more with acupuncture than with breath-awareness meditation (P < .001).
  • No significant between-group difference was found in systolic blood pressure (P = .686), diastolic blood pressure (P = .998), or pulse rate (P = .925).

Why it matters

The trial suggests that acupuncture at these two points may reduce anxiety symptoms in adults with GAD over a short intervention period, while measured cardiovascular functions did not differ significantly from the comparison group. The findings distinguish the reported anxiety outcome from cardiovascular effects and may inform further evaluation of this specific acupuncture approach.

What to keep in mind

The intervention and follow-up were limited to 10 days, and the abstract does not report the magnitude of the anxiety-score change.

Source

Published in Int J Psychiatry Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.